EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study

Pim Rozendal iD, Hanneke Kievit, Paul van der Leest, Idris Bahce iD, Michiel Pegtel, Harry J M Groen iD, Léon C van Kempen iD, T Jeroen N Hiltermann iD, Ed Schuuring iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26168087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pim Rozendal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Netherlands, Roche Diagnostics Nederland B.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are a key treatment for advanced non-small cell lung cancer (NSCLC), but most patients will ultimately experience disease progression due to acquired resistance to ICI. Clinically, it is relevant to differentiate between systemic progression (SP) and oligoprogression (OP). Following SP, ICI treatment is usually discontinued, while in OP, patients are preferably treated with local ablative treatment with continuation of the ICI treatment. However, with progressive disease, it remains difficult to differentiate between true OP or SP. Circulating tumor DNA (ctDNA) analysis provides an accurate real-time reflection of the tumor burden. It remains elusive if ctDNA abundance and/or dynamics can discriminate between OP and SP. Therefore, the aim of this exploratory cohort study is to evaluate whether the sequential molecular tumor profiling of ctDNA is suitable for discriminating between true OP and SP in advanced NSCLC. Patients with stage III/IV NSCLC showing progression after ≥3 months of ICI were included. OP was defined retrospectively by RECIST response ≥ 6 months after local treatment and continued ICIs. Serial plasma samples were analyzed using the AVENIO ctDNA Expanded NGS assay targeting 77 cancer-related genes. Twenty patients (6 OP, 14 SP) were included. Somatic alterations were detected in 16 patients (median 4 mutations). No significant differences in baseline ctDNA levels, changes at progression, or mutation patterns were observed between OP and SP. Although ctDNA levels generally decreased early after the start of ICI treatment, and were increased at disease progression, mutational profiles of the 77 genes using the AVENIO Expanded ctDNA panel did not distinguish OP from SP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsHigh-Throughput Nucleotide SequencingCirculating Tumor DNAHumansMaleAgedFemaleDisease ProgressionMiddle AgedBiomarkers, TumorRetrospective StudiesMutationAged, 80 and overAdult

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)immune checkpoint inhibitors (ICIs)next-generation sequencing (NGS)non-small cell lung cancer (NSCLC)oligoprogression

Substanzen

Immune Checkpoint InhibitorsCirculating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, VU University, 1081 HV Amsterdam, The Netherlands.

ORCID-Profile: Pim Rozendal, Idris Bahce, Harry J M Groen, Léon C van Kempen, T Jeroen N Hiltermann, Ed Schuuring

Förderung

  • Roche Netherlands
  • Roche Diagnostics Nederland B.V.

Zitieren

APA

Rozendal, P., Kievit, H., van der Leest, P., Bahce, I., Pegtel, M., Groen, H. J. M., van Kempen, L. C., Hiltermann, T. J. N., & Schuuring, E. (2025). Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26168087

Vancouver

Rozendal P, Kievit H, van der Leest P, Bahce I, Pegtel M, Groen HJM, et al. Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26168087

BibTeX
@article{Rozendal2025,
  author = {Rozendal, Pim and Kievit, Hanneke and van der Leest, Paul and Bahce, Idris and Pegtel, Michiel and Groen, Harry J M and van Kempen, Léon C and Hiltermann, T Jeroen N and Schuuring, Ed},
  title = {Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26168087}
}
Kostenlos starten →